Drug development for the treatment of amyloid lateral sclerosis (ALS) requires an understanding of how genetic mutations lead to the ALS phenotype. Researchers use human induced pluripotent stem cell (iPSC)-derived models to create genetically accurate disease models for which genotype and phenotype are closely matched. However, this process can be complicated by laborious procedures, cell differentiation variability, heterogenous cell populations, and poor genotype-phenotype matches. A system that enables researchers to measure phenotypic changes relevant to ALS in physiologically relevant cells is fundamental to high-throughput disease and drug discovery efforts.

Download this application note from bit.bio to learn how researchers used a microelectrode array platform to identify functional phenotypes, including neural activity and connectivity in human iPSC-derived ALS models.

Sponsored by